fAUC/MIC is the most predictive pharmacokinetic/pharmacodynamic index of colistin against Acinetobacter baumannii in murine thigh and lung infection models.
about
Treatment Options for Carbapenem-Resistant Enterobacteriaceae InfectionsInhaled Antibiotics for Gram-Negative Respiratory InfectionsColistin: recent data on pharmacodynamics properties and clinical efficacy in critically ill patients.Individualised antibiotic dosing for patients who are critically ill: challenges and potential solutions.Pharmacology of polymyxins: new insights into an 'old' class of antibiotics.'Old' antibiotics for emerging multidrug-resistant bacteriaPopulation pharmacokinetics of colistin methanesulfonate and formed colistin in critically ill patients from a multicenter study provide dosing suggestions for various categories of patientsMelatonin attenuates colistin-induced nephrotoxicity in rats.Dosing of colistin-back to basic PK/PD.Clinically relevant plasma concentrations of colistin in combination with imipenem enhance pharmacodynamic activity against multidrug-resistant Pseudomonas aeruginosa at multiple inocula.Pharmacokinetics/pharmacodynamics of marbofloxacin in a Pasteurella multocida serious murine lung infection model.Pharmacokinetics of colistin in cerebrospinal fluid after intraventricular administration of colistin methanesulfonateThe combination of colistin and doripenem is synergistic against Klebsiella pneumoniae at multiple inocula and suppresses colistin resistance in an in vitro pharmacokinetic/pharmacodynamic modelPharmacokinetics and pharmacodynamics of 'old' polymyxins: what is new?Carbapenemases in Klebsiella pneumoniae and other Enterobacteriaceae: an evolving crisis of global dimensionsVirulence of Acinetobacter baumannii Exhibiting Phenotypic Heterogeneous Growth against Meropenem in a Murine Thigh Infection ModelA survey on infection management practices in Italian ICUsAnthelmintic closantel enhances bacterial killing of polymyxin B against multidrug-resistant Acinetobacter baumannii.Paradoxical Effect of Polymyxin B: High Drug Exposure Amplifies Resistance in Acinetobacter baumanniiSynergistic activity of colistin and rifampin combination against multidrug-resistant Acinetobacter baumannii in an in vitro pharmacokinetic/pharmacodynamic model.Efficacy of Lysophosphatidylcholine in Combination with Antimicrobial Agents against Acinetobacter baumannii in Experimental Murine Peritoneal Sepsis and Pneumonia Models.Polymyxin B Induces Apoptosis in Kidney Proximal Tubular Cells.Antimicrobial Activity and Toxicity of the Major Lipopeptide Components of Polymyxin B and Colistin: Last-line Antibiotics against Multidrug-Resistant Gram-negative BacteriaActivity of Tigecycline in combination with Colistin, Meropenem, Rifampin, or Gentamicin against KPC-producing Enterobacteriaceae in a murine thigh infection model.Colistin resistance of Acinetobacter baumannii: clinical reports, mechanisms and antimicrobial strategies.Bloodstream infections caused by carbapenemase-producing Klebsiella pneumoniae: a clinical perspective.Clinical pharmacokinetics of antibacterials in cerebrospinal fluid.Confronting carbapenemase-producing Klebsiella pneumoniae.Colistimethate sodium dry powder for inhalation: a review of its use in the treatment of chronic Pseudomonas aeruginosa infection in patients with cystic fibrosis.Colistin: understanding and applying recent pharmacokinetic advances.Strategies for the safe use of colistin.Polymyxin B versus colistin: an update.Pharmacokinetics and pharmacodynamics in antibiotic dose optimization.Optimizing Antibiotic Dosing Strategies for the Treatment of Gram-negative Infections in the Era of Resistance.Aerosolized Polymyxin B for Treatment of Respiratory Tract Infections: Determination of Pharmacokinetic-Pharmacodynamic Indices for Aerosolized Polymyxin B against Pseudomonas aeruginosa in a Mouse Lung Infection Model.Therapeutic drug monitoring of anti-infective agents in critically ill patients.Pharmacokinetics/Pharmacodynamics of Pulmonary Delivery of Colistin against Pseudomonas aeruginosa in a Mouse Lung Infection Model.High-intensity meropenem combinations with polymyxin B: new strategies to overcome carbapenem resistance in Acinetobacter baumannii.Predicting and preventing antimicrobial resistance utilizing pharmacodynamics: part II Gram-negative bacteria.Clinical Pharmacokinetics and Pharmacodynamics of Colistin.
P2860
Q28082546-41A5086E-0392-4D5D-B61C-D25576D0D63EQ28386160-EF66FDF5-E1BF-49CC-9BA5-FA79C4D6BA1EQ34015375-E4FEEAAB-395D-4AEF-BAEA-915119FFE631Q34274190-A66706FA-B741-4E21-A725-FF62BD95CDFEQ34346283-D33DE5A8-992B-4742-9A7F-D494B638B6CAQ34565772-94F4FB42-79E0-4524-A2C1-6015A6D105F9Q35065863-3EE7D6D2-813B-48C0-A42B-5F941AB91F95Q35191353-B576A646-9AB1-4F84-A778-0408B1CFEBADQ35242165-BC81A0BA-66B8-428E-95AC-A09BAFAE7811Q35364351-9E9640EB-A8F0-4CD7-9DAC-BB70004D8436Q35859460-4101F03D-AD0F-4692-95D5-65DADE102C6CQ36171581-49B2D948-6400-4689-ABB7-BD2A337B04E9Q36276852-595A5FA7-E908-4842-881A-D2710001D58EQ36335694-47241E3E-6FE0-47B3-8F1D-B9CCE427A72CQ36361921-2488FA4A-644D-451B-A533-BE0CBE32C36BQ36683476-FD5949E5-7344-4650-BCE5-5394BE60DF33Q36902763-D49EDD93-ADBC-41A7-826C-8AC9E0143BDDQ37014270-068B2735-13F6-4F90-BA47-E425381A821AQ37023206-2A8F5194-3A63-4CDE-B615-97769DE65B78Q37036489-DE44C81D-447F-4629-BBA5-F347932256E8Q37120088-1BC960E4-B442-42A0-B8E0-9B1E9F3C8573Q37124019-78027713-8A30-4E89-8106-6EA373E25827Q37165591-AD19B961-1951-49FD-90D2-20707283D704Q37335672-0C5B2468-A12F-45FD-96AF-50F348ADA704Q37996299-04B27313-1DFE-47AD-A7CC-E4F6366AD4ACQ38068604-B7D2C2C1-3A93-4E90-8E22-1F6F42CF3050Q38100704-15ACCF51-CF64-423F-AEE0-6B8EAFD16FF7Q38135903-91940BBA-7A55-455B-BA25-8DE6B791D0C3Q38186636-7848DE24-032C-41DF-A54F-1872537AED40Q38246001-9FC3451B-8874-4F34-B917-F56DF0AA8539Q38548658-9F41ADA3-A568-4B65-9A32-6DE2AB762C7EQ38613051-258D4728-DB74-45B0-976F-0B6CF12B1F8BQ38664871-CD0ACC0D-D7E6-4DE1-B38D-84E2BD3B4634Q38672016-55CE82B4-DD37-4F56-BB88-11D77EEADECAQ38755683-E6A5B08B-F4C1-4DAA-936B-4FB00EB179ABQ38790740-0FA05313-7471-44E4-AF5A-1A6C44AD1D52Q39057108-BDC6A877-C033-4D71-BD4B-076F6A04921BQ39170967-9A39486F-CA5F-4E07-803D-4988361BFD0FQ39293585-4E48765D-930C-43A3-93C0-AA9B3B3866C4Q39333751-50BE3580-DC05-4368-AF14-569979F12117
P2860
fAUC/MIC is the most predictive pharmacokinetic/pharmacodynamic index of colistin against Acinetobacter baumannii in murine thigh and lung infection models.
description
2010 nî lūn-bûn
@nan
2010 թուականի Յունիսին հրատարակուած գիտական յօդուած
@hyw
2010 թվականի հունիսին հրատարակված գիտական հոդված
@hy
2010年の論文
@ja
2010年論文
@yue
2010年論文
@zh-hant
2010年論文
@zh-hk
2010年論文
@zh-mo
2010年論文
@zh-tw
2010年论文
@wuu
name
fAUC/MIC is the most predictiv ...... igh and lung infection models.
@ast
fAUC/MIC is the most predictiv ...... igh and lung infection models.
@en
fAUC/MIC is the most predictiv ...... igh and lung infection models.
@nl
type
label
fAUC/MIC is the most predictiv ...... igh and lung infection models.
@ast
fAUC/MIC is the most predictiv ...... igh and lung infection models.
@en
fAUC/MIC is the most predictiv ...... igh and lung infection models.
@nl
prefLabel
fAUC/MIC is the most predictiv ...... igh and lung infection models.
@ast
fAUC/MIC is the most predictiv ...... igh and lung infection models.
@en
fAUC/MIC is the most predictiv ...... igh and lung infection models.
@nl
P2860
P356
P1476
fAUC/MIC is the most predictiv ...... high and lung infection models
@en
P2093
John D Turnidge
Rajesh V Dudhani
P2860
P304
P356
10.1093/JAC/DKQ226
P407
P577
2010-06-23T00:00:00Z